Your browser doesn't support javascript.
loading
Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
Gilmartin, Christopher Gs; Hoyle, Natasha; Garjani, Afagh; Dixon, Terri; Jos, Helena; Paling, David; Brownlee, Wallace; Tench, Christopher; Evangelou, Nikos.
Afiliación
  • Gilmartin CG; Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK.
  • Hoyle N; Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Garjani A; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Dixon T; Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK.
  • Jos H; Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Paling D; Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Brownlee W; University College London Medical School, London, UK.
  • Tench C; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Evangelou N; Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK.
Mult Scler ; 30(4-5): 600-604, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38323423
ABSTRACT

BACKGROUND:

Siponimod-related lymphopenia in real-world clinical practice has implications for dose adjustment and infection risk.

OBJECTIVE:

To characterise siponimod-related lymphopenia in people with secondary progressive multiple sclerosis (pwSPMS).

METHODS:

This is a retrospective cohort of 188 pwSPMS. The development of grade 4 lymphopenia was interrogated with Kaplan-Meier survival analysis and binary logistic regression.

RESULTS:

Lymphopenia develops soon after commencing siponimod. In total, 15 (8.5%) of 176 experienced grade 4 lymphopenia at 1 month after initiation. There were no clinically significant associations between patient characteristics and development of grade 4 lymphopenia.

CONCLUSION:

Grade 4 lymphopenia can occur soon after siponimod initiation and cannot be predicted.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Azetidinas / Compuestos de Bencilo / Esclerosis Múltiple Crónica Progresiva / Linfopenia / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Azetidinas / Compuestos de Bencilo / Esclerosis Múltiple Crónica Progresiva / Linfopenia / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido